Damora Therapeutics, Inc. is a biopharmaceutical company developing therapies for hematologic disorders, with a primary focus on myeloproliferative neoplasms (MPNs). The company’s lead product candidate, DMR-001, is a monoclonal antibody targeting mutant forms of the calcium binding protein calreticulin (mutCALR) for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF). Damora holds exclusive worldwide development and commercialization rights to DMR-001 under a licensing agreement with Paragon Therapeutics, Inc., which also oversees research activities for the pipeline. The company is advancing DMR-002 and DMR-003, additional mutCALR-targeting candidates, with plans to submit Investigational New Drug Applications or Clinical Trial Applications for these assets in 2026 and 2027. Damora has initiated the Phase 1/1b CLARITY-101 clinical trial for DMR-001 in patients with mutCALR-driven ET and MF. The company’s pipeline previously included small molecule inhibitors for acute myeloid leukemia, such as GB3226, which have been deprioritized in favor of the mutCALR portfolio. Damora targets the United States market for mutCALR-driven ET and MF, addressing a significant unmet medical need in chronic blood cancers.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ir.damoratx.com
Sector Healthcare IR page ir.damoratx.com
Tags
hematologic disorders, myeloproliferative neoplasms, essential thrombocythemia, myelofibrosis, monoclonal antibodies, calreticulin mutations, targeted therapy, biologics, clinical development, DMR-001, DMR-002, DMR-003, GB3226, GB1211, GB2064, CLARITY-101, Paragon Therapeutics Inc., Paramora Holding LLC
Press page —

Metrics

Valuation  
Market cap $ 1.317B
Market cap (USD) $ 1.317B
P/E 2.25
PEG —
P/BV 2.66
P/S —
P/OCF -22.28
P/FCF -30.54
Dividend yield —
Turnover / mcap —
Returns  
ROE -163.8%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 260.527M 17.132M 38.227M 73.188M 122.215M 171.596M 56.609M
Net profit -209.839M -21.439M -38.349M -61.624M -51.752M -34.837M -36.507M
Free cash flow — — — -43.128M -52.531M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price — 0.47 0.72 1.15 3.03 12.51 —
Price performance 12m — -0.34 -0.37 -0.62 -0.76 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 298,000 915,000 847,000 804,000 249,000 73,000 68,000
Cash and deposits (USD) 31.1M 11.3M 164M 62.6M 32.8M 21.5M 14.2M 258M
Right-of-use assets (USD) — 298,000 885,000 834,000 810,000 247,000 73,000 68,000
Cash flow detail
Operating cash flow (USD) — -19.3M -38.2M -52.3M -42.9M -36.9M -18.6M -6.73M
Purchases of property, plant and equipment (USD) — — — -223,000 -196,000 — — —
Change in payables (cash effect) (USD) — 1.94M -477,000 -1.32M 1.82M -1.65M -1.33M 51,000
Income taxes paid (cash effect) (USD) — — — — — — — -5,000
Share-based compensation (USD) — — 982,000 4.48M 5.57M 5.43M 3.24M 998,000
Free cash flow (OCF - PPE - intangibles) (USD) — — — -52.5M -43.1M — — —
Income detail
Research and development expense (USD) — 19.7M 24.6M 38.5M 48.2M 23.8M 6.4M 26.9M
↳ 5y CAGR -20.2% +1.8%
Total comprehensive income (USD) — -37.3M -31.7M -52.7M -61.5M -37.7M -21.7M -209M
Comprehensive income to owners (USD) — -37.3M -31.7M -52.7M -61.5M -37.7M -21.7M -209M
Reported Dec 11, 2020 Mar 29, 2021 Mar 29, 2021 Feb 17, 2022 Mar 9, 2023 Mar 8, 2024 Mar 19, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of options to purchase an aggregate of 144,400 Damora ordinary shares with a 10-year term and an exercise price of $21.28 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.

About Damora Therapeutics

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to three newly-hired, non-executive employees on September 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of options to purchase an aggregate of 135,400 Damora ordinary shares with a 10-year term and an exercise price of $28.18 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.

– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) –

– Presented DMR-001 preclinical data at the European Hematology Association (EHA) 2026 Congress, showcasing best-in-class potential –

– Appointed biotech veteran Dr. Andrew Cheng to the Board of Directors –

– Strong financial position with $540.5 million in cash and cash equivalents as of June 30, 2026, expected to fund operations into the second half of 2029 –

WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the quarter ended June 30, 2026, and recent corporate highlights.

“Following the recent achievement of our first major clinical milestone – the initiation of the CLARITY-101 trial of DMR-001 in patients with mutCALR-driven myeloproliferative neoplasm (MPNs) – we are moving with urgency to advance development of this potentially best-in-class long-acting anti-mutCALR antibody because we know patients are waiting,” said Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics. “At the EHA 2026 Congress in June, we presented preclinical data that showed clear differentiation for DMR-001, including best-in-class potency across both major mutation subtypes and a half-life predicted to enable convenient, once-monthly subcutaneous dosing. Advancing from the presentation of these data into the clinic within weeks reflects the pace we intend to keep, and we’re eager to present initial clinical evidence of DMR-001’s unique potential beginning in mid-2027.”

Recent Business Highlights

  • Initiated the global Phase 1/1b CLARITY-101 trial to evaluate the safety, tolerability and efficacy of DMR-001 in patients with mutCALR-driven ET and MF, based on receipt of health authority approval. The Phase 1 dose escalation portion of the trial is designed to rapidly identify a recommended dose for expansion cohorts, with a starting dose of 100 mg (subcutaneous, monthly) expected to be in the range of anticipated therapeutic exposure and an adaptive Bayesian design enabling cohort enrichment. The planned Phase 1b expansion portion of the trial will further evaluate the safety and efficacy of DMR-001 in additional populations and settings, including in early-line disease and in combination with other therapies. Read the press release here.

  • Presented DMR-001 preclinical data at the EHA 2026 Congress (Abstract PF873), highlighting its best-in-class potential. In head-to-head preclinical studies versus a reference anti-mutCALR antibody, DMR-001 showed up to 30-fold higher binding affinity for mutCALR, 26-fold greater inhibition of cellular proliferation in Type 2 mutCALR, and five-fold longer half-life in non-human primates. Based on these data, DMR-001 is predicted to have robust activity across mutCALR subtypes with convenient once-monthly subcutaneous dosing. See the poster presentation here.

  • Appointed Andrew Cheng, M.D., Ph.D., to the Board of Directors. Dr. Cheng has served as President, Chief Executive Officer and Chairman of the Board of Avere Therapeutics since 2026. He previously served as President and Chief Executive Officer of Akero Therapeutics, Inc. from 2018 until its acquisition by Novo Nordisk in December 2025, where he also served on the board of directors. Prior to Akero, Dr. Cheng spent nearly two decades at Gilead Sciences, Inc., including as Senior Vice President from 2009 to 2015, Executive Vice President from 2015 to 2018, and Chief Medical Officer in 2018. Dr. Cheng has served on the board of directors of Vera Therapeutics, Inc. since 2017, where he chairs the nominating and corporate governance committee. Dr. Cheng received his M.D. and Ph.D. from Columbia University College of Physicians and Surgeons and completed his internal medicine residency at the University of California, Los Angeles.

Anticipated Milestones

  • DMR-002 (Fc enhanced, half-life extended anti-mutCALR monoclonal antibody): first regulatory submission expected in the second half of 2026

  • DMR-003 (T-cell engager anti-mutCALR/CD3 bispecific antibody): first regulatory submission expected in 2027

  • Two clinical proof-of-concept datasets for DMR-001 (Fc null, half-life extended anti-mutCALR monoclonal antibody) anticipated beginning mid-2027

Second Quarter 2026 Financial Results

Financial results for the second quarter of 2026 follow the acquisition of rights to the Company’s anti-mutCALR portfolio, appointment of new board and executive leadership, and the renaming of the Company, together completed in the first quarter of 2026.

**Cash Position:**Cash and cash equivalents were approximately $540.5 million as of June 30, 2026. The Company anticipates that its cash and cash equivalents will be sufficient to fund operations into the second half of 2029. Net cash used in operating activities was $21.9 million for the second quarter of 2026.

**R&D Expenses:**Research and development expenses were $25.5 million for the three months ended June 30, 2026, compared to $1.5 million for the three months ended June 30, 2025. The increase was primarily driven by increased preclinical research, manufacturing and personnel costs, including non-cash stock-based compensation charges of $4.5 million related to a warrant obligation pursuant to the Antibody Discovery and Option Agreement that the Company has with Paragon Therapeutics and $1.5 million related to personnel.

**G&A Expenses:**General and administrative expenses were $9.5 million for the three months ended June 30, 2026, compared to $2.0 million for the three months ended June 30, 2025. The increase was primarily driven by increased personnel costs, along with increased professional fees. Non-cash stock-based compensation (personnel-related) increased by $4.5 million for the three months ended June 30, 2026.

Total Other Income: Other income was $4.1 million for the three months ended June 30, 2026, compared to less than $0.1 million for the three months ended June 30, 2025. The increase of $4.1 million was due to increased interest income because of the recent financings.

**Net Loss:**Net loss for the three months ended June 30, 2026, was $31.2 million, compared to $3.4 million for the three months ended June 30, 2025.

Prompts

Damora Therapeutics, Inc. (ticker DMRA), listed in United States.

Company History

Date Change Detail
Mar 19, 2026 Renamed GALECTO, INC. → DAMORA THERAPEUTICS, INC.
— Former tickers GLTO

ETFs Holding Damora Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
WCEO 0.17% 588 $ 17.046K Jul 31, 2026
FFSM 0.07% 37,030 $ 1.073M Jul 31, 2026
VFMO 0.06% 41,532 $ 1.17M Aug 31, 2026
MSSM 0.01% 2,501 $ 70.478K Aug 31, 2026